Secretary's Advisory Committee on Human Research Protections

Secretary's Advisory Committee on Human Research Protections
Name	Secretary's Advisory Committee on Human Research Protections
Formation	2005
Type	Advisory committee
Headquarters	Washington, D.C.
Leader title	Chair
Parent organization	United States Department of Health and Human Services

Secretary's Advisory Committee on Human Research Protections is a federal advisory committee established to advise the United States Department of Health and Human Services and the Secretary of Health and Human Services on issues related to the protection of human subjects in research. The committee has examined policies related to the Common Rule, National Institutes of Health, Food and Drug Administration, Office for Human Research Protections, and other agencies involved in human subjects protections, producing recommendations that have influenced regulations and guidance across American Medical Association, American Psychological Association, and academic institutions such as Harvard University and Johns Hopkins University.

History

The committee was created in the context of evolving federal policy after historical events including the Tuskegee Syphilis Study, the development of the Nuremberg Code, and the promulgation of the Belmont Report. Early precedents trace to advisory panels formed during the administrations of Richard Nixon and Jimmy Carter that influenced the National Research Act. Formal establishment responded to recommendations emerging from interactions among the Department of Defense, Veterans Health Administration, Centers for Disease Control and Prevention, and the National Bioethics Advisory Commission. The committee’s work intersected with regulatory milestones such as revisions to the Common Rule during the administrations of George W. Bush and Barack Obama, and with policy debates involving the HeLa cells controversies and the governance frameworks used by institutions like Massachusetts Institute of Technology and Stanford University.

Membership and Organization

Membership has included bioethicists, clinicians, legal scholars, and consumer advocates drawn from institutions such as Yale University, Columbia University, University of California, San Francisco, Duke University, University of Pennsylvania, University of Michigan, and University of Chicago. Chairs and members have included figures affiliated with organizations like the American College of Physicians, the Association of American Medical Colleges, the American Bar Association, and the National Academy of Medicine. The committee operates under Federal Advisory Committee Act procedures coordinated with the Office of Management and Budget and General Services Administration; meetings are announced in coordination with the Federal Register. Subcommittees and task forces have focused on areas tied to agencies such as the National Science Foundation, Department of Energy, Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services.

Roles and Responsibilities

The committee provides advice to the Secretary of Health and Human Services, the Assistant Secretary for Health, the Office for Human Research Protections, and agency leaders in organizations like the Food and Drug Administration and the National Institutes of Health. Responsibilities include reviewing policy questions related to the Common Rule, consent processes used in clinical trials overseen by Biopharmaceutical companies and academic centers such as University of California, Los Angeles, assessing protections for vulnerable populations including patients in Veterans Health Administration systems and participants in clinical trials sponsored by entities like Pfizer and Moderna, and advising on data-sharing policies implicated by repositories at institutions like the Broad Institute. The committee has examined human subjects protections in research involving technologies developed at places like MIT Media Lab and in collaborations with international bodies including the World Health Organization and the European Commission.

Key Recommendations and Reports

Notable recommendations addressed revisions to the Common Rule, proposals to modernize informed consent similar to frameworks promoted by OECD, and guidance on single‑IRB models reflecting practices used in multi‑site studies led by institutions such as University of Pittsburgh and Vanderbilt University Medical Center. Reports have tackled topics including the ethics of research with biospecimens invoked by controversies around Henrietta Lacks, protections for children as outlined in guidance comparable to Children's Oncology Group standards, and safeguards for research in emergency settings resembling protocols employed by Department of Defense clinical programs. Recommendations have been cited in rulemaking documents and guidance by the Office for Human Research Protections, the Food and Drug Administration, and the National Institutes of Health.

Interactions with Federal Agencies and Policy Impact

The committee has engaged with federal agencies including the National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention, Department of Defense, Veterans Health Administration, and National Science Foundation to harmonize human subjects protections across research portfolios. Its advice influenced the adoption of single‑IRB policies used in NIH multi‑site grants, informed consent elements harmonized with FDA requirements, and deliberations around broad consent and data privacy that intersected with Health Insurance Portability and Accountability Act of 1996 considerations and National Academy reports. The committee’s input figured into interagency deliberations with entities like the Office of Management and Budget on research data stewardship and with the Federal Drug Administration on trial oversight frameworks.

Controversies and Criticisms

Critiques have addressed perceived conflicts between recommendations and operational constraints at institutions such as academic medical centers and private sponsors including pharmaceutical companies; debates paralleled controversies involving oversight failures in high‑profile incidents like cases reviewed by the Inspector General and disputes over biospecimen consent reminiscent of the Havasupai Tribe litigation. Observers from organizations including the American Civil Liberties Union and consumer advocacy groups have raised concerns about representation on the committee and the transparency of deliberations, while legal scholars from institutions such as Georgetown University and Stanford Law School have questioned the legal basis for some advisory recommendations. Some stakeholders argued that recommendations strained resources of Institutional Review Boards at universities like Rutgers University and Ohio State University, and critiques from professional associations such as the American Psychological Association focused on impacts to behavioral research methodologies. Congress of the United States oversight hearings have occasionally scrutinized committee influence on regulatory actions.

Category:United States federal advisory committees